Bin Yang

Executive Director Chemistry @ Kymera Therapeutics

About

https://scholar.google.com/citations?user=ddJkHZAAAAAJ&hl=en • Experienced medicinal chemist and drug discovery leader with a track record of delivering clinical development candidates, including KT-621 (STAT6 degrader, Phase II), KT-333 (STAT3 degrader, Phase I), camizestrant (AZD9833, selective estrogen receptor degrader, Phase III), AZD4573 (CDK9 inhibitor, phase II), AZD3463 (ALK inhibitor), AZD8542 (Smoothened antagonist), and AZD7254 (Smoothened antagonist). • Insights in multiple drug discovery scientific fields outside chemistry including ADME, pharmaceutical science, drug safety, cancer biology, and intellectual property. • Extensive experience as lead chemist in protein degradation projects, including molecular glue and PROTACs optimization for oral bioavailability.

Country

United States

City

Lexington

Industry

Pharmaceuticals

Skill

Drug Discovery, Pharmaceutical Industry, Organic Chemistry, Medicinal Chemistry, Chemistry, Biotechnology, ADME, Cancer

Experience

Executive Director Chemistry

Kymera Therapeutics

2024-2 - Present · 2 yrs 8 mos

Watertown, Massachusetts, United States

Senior Director

Kymera Therapeutics

2022-4 - 2024-1 · 1 yr 10 mos

United States

Director Of Chemistry

Kymera Therapeutics

2021-1 - 2022-4 · 1 yr 4 mos

Cambridge, MA

• Experienced medicinal chemist with a track record of leading teams and delivering clinical candidate drugs, including AZD9833 (selective estrogen receptor degrader), AZD4573 (CDK9 inhibitor), AZD3463 (ALK inhibitor), AZD8542 (Smoothened antagonist), and AZD7254 (Smoothened antagonist). • Insights in multiple drug discovery scientific fields outside chemistry including ADME, pharmaceutical science, drug safety, cancer biology, and intellectual property. • Extensive experience as lead chemist in protein degradation projects, including molecular glue and PROTACs optimization for oral bioavailability.